Details of the Drug
General Information of Drug (ID: DMHWD2C)
Drug Name |
4-(2-(pyrrolidin-1-yl)ethyl)pyridine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
67580-65-8; 4-[2-(pyrrolidin-1-yl)ethyl]pyridine; 4-(2-Tetrahydro-1H-pyrrol-1-ylethyl)pyridine; 4-(2-pyrrolidin-1-ylethyl)pyridine; MLS000737070; CHEMBL405070; 4-(2-(pyrrolidin-1-yl)ethyl)pyridine; 4-(2-pyrrolidin-1-yl-ethyl)-pyridine; NSC42776; AC1Q4WU8; AC1Q28PY; AC1L60Z5; SCHEMBL3993201; 4-(2-pyrrolidinylethyl)pyridine; CTK2F7988; DTXSID30285782; MolPort-000-145-638; ZINC163336; HMS2752A23; SBB089201; BDBM50372345; STL324986; NSC-42776; AKOS006227946; VP14627; MCULE-2911571696; 4-(2-PYRROLIDINOETHYL)PYRIDINE; SMR000038089
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 176.26 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||